Hello. This is Daily Stock.
Today, the domestic stock market experienced extreme volatility due to concerns over high global interest rates and outflows of foreign capital.
[Image: /stdaily/uploads/202606/gen_6a2676d12d4578.84092915.png]
Key Takeaways
- **Imminent FDA Drug Approval Milestones**: The Prescription Drug User Fee Act (PDUFA) target action date for the FDA's resubmission review of HLB’s combination therapy of 'Rivoceranib and Camrelizumab' as a first-line treatment for liver cancer is approaching on July 23, 2026.
- **Pipeline Progress Becoming Visible**: 'Lirafugratinib', a second-line treatment for cholangiocarcinoma (bile duct cancer), has entered FDA Priority Review, with an approval decision expected by September 27, 2026.
- **Relative Resilience Amid Market Crash**: On June 8, 2026, when the KOSDAQ index plunged 9.08% to close at 911.39 and triggered a circuit breaker, HLB closed down 4.55% at 48,300 KRW, demonstrating solid downside support compared to peer biotech stocks.
---
Current Status Summary
HLB is currently facing its two most critical commercialization milestones nearly 20 years after commencing anticancer drug development.
The first core pillar, the 'Rivoceranib + Camrelizumab' combination therapy for first-line liver cancer, completed its resubmission to the FDA in January and is currently undergoing final review.
Submissions to address the Chemistry, Manufacturing, and Controls (CMC) issues at China's Hengrui Pharma—which were previously raised by the FDA—have been completed. The company is now waiting for the results of the final CMC reinspection.
[Image: /stdaily/uploads/202606/gen_6a2676dec62db3.39217330.png]
The second pillar, 'Lirafugratinib' (a cholangiocarcinoma treatment), was granted FDA Priority Review on March 30, officially initiating its formal review process.
In its global Phase 2 clinical trial, it demonstrated an Objective Response Rate (ORR) of 47%, proving superior efficacy compared to existing therapies and strengthening the outlook for approval by September.
In addition, HLB participated with a standalone booth at ASCO 2026 (the American Society of Clinical Oncology), the world's largest cancer congress held in Chicago from May 29 to June 2, successfully completing global partnering meetings and pre-marketing efforts.
---
Financial Analysis
HLB’s consolidated financial performance in 2025 showed a dual structure, where improvements in its core business conflicted with equity-method valuation losses from affiliates.
Driven by growth in the medical devices and composite materials divisions, revenue increased by 23.17% year-on-year to 83.9 billion KRW, and the operating loss narrowed to 106.9 billion KRW.
However, due to substantial non-operating expenses from valuation losses on convertible bond (CB) derivatives and equity-method losses on associates, the net loss widened to 241.5 billion KRW.
With the increase in total liabilities, the debt-to-equity ratio rose from 36.1% at the end of 2024 to 90.1% at the end of 2025. Nonetheless, as of Q1 2026, profitability showed signs of recovery, with the operating loss decreasing by 19.3% year-on-year.
| Classification (Consolidated) | 2024 | 2025 | YoY Change (%) |
|---|---|---|---|
| **Revenue** | 68.1 billion KRW | 83.9 billion KRW | +23.17% |
| **Operating Loss** | 118.5 billion KRW | 106.9 billion KRW | -9.73% (Narrowed deficit) |
| **Net Loss** | 108.0 billion KRW | 241.5 billion KRW | +123.61% (Widened deficit) |
| **Debt-to-Equity Ratio** | 36.1% | 90.1% | +54.0%p |
---
Valuation
As of June 8, 2026, HLB's closing price was 48,300 KRW, with a market capitalization of approximately 6.4334 trillion KRW.
Compared to its annual revenue scale of around 80 billion to 100 billion KRW, a market cap exceeding 6 trillion KRW places it in an overvalued territory under traditional multiple metrics (such as PSR).
However, this is a valuation model characteristic of early-stage biotech firms, reflecting market expectations for future commercialization royalties and direct sales revenue worth hundreds of billions of KRW annually following potential FDA approval.
If HLB secures successive approvals in July and September, a valuation re-rating could begin in earnest as actual prescription revenues start to materialize in the global market.
Conversely, if this third attempt is delayed or rejected, liquidity risks could emerge, potentially leading to a sharp contraction in its valuation multiple.
---
Expert & Institutional Analysis
Securities analysts and pharmaceutical industry experts define HLB’s 'third attempt for the liver cancer drug' as a watershed moment that will test the capability of the domestic biotech industry to penetrate the global oncology market.
The consensus is that the clinical data itself is highly competitive.
The median overall survival (mOS) of the combination therapy with Camrelizumab reached 23.8 months, which, compared to other recently approved competitive options, suggests strong market penetration potential in terms of both safety profile and efficacy.
Regardless of the drug approval outcome, institutional investors are paying close attention to HLB’s recent efforts to optimize its business structure, including affiliate mergers, which are seen as preparation for transitioning into a fully commercialized pharmaceutical group.
---
Risk Factors
1. Passing the Chemistry, Manufacturing, and Controls (CMC) Inspection
The most critical variable is whether Hengrui Pharma's production line for Camrelizumab passes the FDA's CMC inspection. Since the previous two Complete Response Letters (CRLs) were triggered by sterilization and quality control consistency issues in the manufacturing process, the company must fully overcome this final inspection barrier.
2. High Exchange Rates & Macroeconomic Headwinds
With the USD/KRW exchange rate reaching a high of 1,533.70 KRW, the financial burden of overseas clinical development and commercialization preparation costs could increase.
3. Extreme Market Volatility
Currently, the KOSPI Fear & Greed Index is at Extreme Fear (21.6), and the Nasdaq Fear & Greed Index is also subdued at Neutral (42.1). Market supply-demand instability, including concerns over margin calls due to the liquidation of KOSDAQ credit loan balances, could cause irrational volatility in HLB's share price.
---
Investment Outlook Summary
HLB is aiming for a historic milestone where a Korean biotech firm moves beyond simple technology licensing-out (L/O) to simultaneously secure global direct distribution networks and self-approved novel drugs.
If the schedules set for July 23 and September 27 lead to approvals, it could serve as a catalyst for HLB to leap from a single biotech firm into a global pharmaceutical player.
However, since the market is in a state of extreme fear and drug approval remains the sole jurisdiction of regulatory bodies, a split-entry approach considering volatility appears more prudent than aggressive chasing.
---
Investor Checklist Q&A
Q1. When exactly is the FDA's final decision date for Rivoceranib in July?
- The final review deadline under the FDA's Prescription Drug User Fee Act (PDUFA) is **July 23, 2026**.
Q2. What was the reason for the previous approval delay of the Rivoceranib liver cancer combination therapy?
- It was due to issues concerning sterilization processes and quality control consistency raised during the CMC inspection of 'Camrelizumab', the immunotherapy manufactured by HLB's partner, Hengrui Pharma.
Q3. What kind of drug is 'Lirafugratinib', which faces an approval decision in September?
- It is a novel second-line treatment for cholangiocarcinoma targeting FGFR2 genetic alterations. It was granted FDA Priority Review in March, with an approval decision expected **by September 27, 2026**.
Q4. What is behind the widened net loss in HLB’s recently announced 2025 financial results?
- While core revenue grew to 83.9 billion KRW and the operating deficit narrowed, significant one-off non-operating expenses were recognized, including fair value losses on financial derivatives (such as convertible bonds) and valuation losses on associates.
Q5. How did HLB's stock perform during the Black Monday crash on June 8, 2026?
- Amid an extreme sell-off where the KOSDAQ index plunged 9.08%, HLB closed **down 4.55% at 48,300 KRW**, showing relative resilience compared to other large-cap stocks in terms of market capitalization.
---